WO1994004181A1 - Neutralisation de l'heparine au moyen de peptides multimeres - Google Patents

Neutralisation de l'heparine au moyen de peptides multimeres Download PDF

Info

Publication number
WO1994004181A1
WO1994004181A1 PCT/US1993/007653 US9307653W WO9404181A1 WO 1994004181 A1 WO1994004181 A1 WO 1994004181A1 US 9307653 W US9307653 W US 9307653W WO 9404181 A1 WO9404181 A1 WO 9404181A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
heparin
leucine
peptides
lysine
Prior art date
Application number
PCT/US1993/007653
Other languages
English (en)
Inventor
James Boyd
Original Assignee
Repligen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corporation filed Critical Repligen Corporation
Priority to AU50112/93A priority Critical patent/AU5011293A/en
Publication of WO1994004181A1 publication Critical patent/WO1994004181A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • LAPF4 monomeric low-affinity platelet factor 4
  • PF4 and recombinant PF4 were prepared as described previously (Cooke et al., Circulation, 85:1102- 1109, 1992).
  • polypeptides containing two or more domains each of which contains the peptide sequence of the invention, connected by three or more amino acids which are capable of forming a loop (e.g., Pro-Arg-Arg) .
  • Such polypeptides are capable of folding in a unimolecular rather than multimolecular manner to form a three-dimensional helical bundle of peptide domains which may interact with and neutralize heparin.
  • the invention also includes peptides which are produced by recombinant techniques. For example, DNA sequences encoding the peptide can be generated using standard methods well known to those skilled in the art (see for example, Ausebel et al..

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un peptide pouvant neutraliser les effets anticoagulants de l'héparine, et qui présente la séquence Y X1 X2 Y X3 X4 X5 Y X6 X7 Y dans laquelle (a) chaque Y est indépendamment choisi dans le groupe composé de leucine, isoleucine, valine, phénylalanine, tyrosine et tryptophane, et (b) chaque X est indépendamment choisi dans le groupe composé d'alanine, arginine, asparagine, cystéine, glutamine, glycine, histidine, isoleucine, leucine, lysine, méthionine, phénylalanine, sérine, thréonine, tryptophane, tyrosine et valine. Des procédés permettant de neutraliser les effets anticoagulants de l'héparine chez un mammifère à l'aide du peptide de l'invention sont également revendiqués.
PCT/US1993/007653 1992-08-17 1993-08-13 Neutralisation de l'heparine au moyen de peptides multimeres WO1994004181A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50112/93A AU5011293A (en) 1992-08-17 1993-08-13 Heparin neutralization with multimeric peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93245692A 1992-08-17 1992-08-17
US07/932,456 1992-08-17

Publications (1)

Publication Number Publication Date
WO1994004181A1 true WO1994004181A1 (fr) 1994-03-03

Family

ID=25462356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007653 WO1994004181A1 (fr) 1992-08-17 1993-08-13 Neutralisation de l'heparine au moyen de peptides multimeres

Country Status (2)

Country Link
AU (1) AU5011293A (fr)
WO (1) WO1994004181A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448717C1 (ru) * 2011-04-20 2012-04-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Способ получения антикоагулянтно-фибринолитического средства на основе гепарина

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, Volume 240, No. 1, issued July 1985, J. LOSCALZO et al., "Interaction of Platelet Factor Four and Glycosaminoglycans", pages 446-455. *
ARTERIOSCLEROSIS, Volume 9, No. 1, issued January/February 1989, A.D. CARDIN et al., "Molecular Modeling of Protein-Glycosaminoglycan Interactions", pages 21-30. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448717C1 (ru) * 2011-04-20 2012-04-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Способ получения антикоагулянтно-фибринолитического средства на основе гепарина

Also Published As

Publication number Publication date
AU5011293A (en) 1994-03-15

Similar Documents

Publication Publication Date Title
US10774124B2 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
Hofsteenge et al. Amino acid sequence of the ribonuclease inhibitor from porcine liver reveals the presence of leucine-rich repeats
US4749780A (en) Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP1379266B1 (fr) Annexines modifiees et prevention de la thrombose
EP0255206B1 (fr) Peptides inhibant la liaison du facteur von Willebrand
JPH04507252A (ja) 抗凝血タンパク質
US5786324A (en) Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
JPH07508404A (ja) ヒト／ブタハイブリッド第ｖｉｉｉ因子
US20030104981A1 (en) Human insulin analogues
US5238919A (en) Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
JP2729498B2 (ja) ヒトインシユリンアナログ類
EP0590048B1 (fr) Un procede pour preparer des fragments therapeutiques du facteur de von willebrand
Cook et al. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.
US5830860A (en) Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
EP0257312A2 (fr) Inhibiteur d'élastase de leucocyte dérivé de cartilage
JP4233114B2 (ja) フォン・ブィレブランド因子の治療用フラグメント
WO1994004181A1 (fr) Neutralisation de l'heparine au moyen de peptides multimeres
US5807982A (en) Affinity purified heparin
US5204321A (en) Heparin neutralization with platelet factor 4
US6239101B1 (en) Thrombin binding polypeptides
JPH0219399A (ja) トロンビン結合ポリピペプチド
JP3276753B2 (ja) カテプシンｌ特異的阻害ポリペプチド
WO2004013303A2 (fr) Proteines d'annexine modifiees, et procedes de traitement de la drepanocytose a crise vaso-occlusive
US20220118063A1 (en) Methods and compositions related to improved factor viii long half-life coagulation complexes
US6982154B2 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA